Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/DMT/Immunology & Inflammation

DMT for Immunology & Inflammation

14 papers and 1 clinical trial exploring dmt as a treatment for immunology & inflammation.

CompoundTryptamine

DMT

A powerful, short-acting tryptamine psychedelic found in many botanical sources, known for rapid onset and intense subjective experiences.

Full DMT profile
IndicationOver 264 million people worldwide suffer from depression, with a significant subset experiencing related inflammatory conditions.

Immunology & Inflammation

Recent research highlights the potential of psychedelics, particularly psilocybin and MDMA, in modulating immune responses and inflammation, shedding light on their therapeutic implications for mood disorders and other immune-related conditions. Studies are beginning to uncover the mechanisms through which these compounds exert anti-inflammatory effects and promote neuroplasticity, particularly in the context of major depressive disorder (MDD).

Full Immunology & Inflammation profile

Academic Research

14 papers
Open Accessindividual

Ayahuasca in the treatment of bipolar disorder with psychotic features-A retrospective case study

This retrospective case study describes a woman with bipolar disorder and psychotic features whose suicidality, dissociation and social isolation markedly improved and were sustained after multiple ayahuasca ceremonies, with corroboration of childhood abuse and ongoing symptom reduction over several years. The report suggests potential therapeutic benefits of ayahuasca for severe traumatisation and bipolar symptoms and situates the case within a brief review of low‑dose ayahuasca and LSD treatment literature.

Published
March 10, 2023
Journal
Psyarxiv
Authors
Turkia, M.
Open Accessindividual

Classic psychedelics do not affect T cell and monocyte immune responses

In vitro exposure to LSD, psilocin, DMT and mescaline did not alter proliferation or stimulated cytokine release of primary human T lymphocytes nor induce NF-κB in monocytes. These results indicate classic psychedelics do not directly modulate key T‑cell or monocyte functions and support their safe use in assisted psychotherapy where immune suppression would be detrimental.

Published
January 20, 2023
Journal
Frontiers in Psychiatry
Authors
Rudin, D., Areesanan, A., Liechti, M. E., Gründemann, C.
Paywallmeta

Significance of mammalian N, N-dimethyltryptamine (DMT): A 60-year-old debate

This review (2022) explores the role of endogenously (within the animal) produced DMT in mammalian physiology by exploring 60 years of research. The biosynthesis of DMT, its receptor activity, and regulation are discussed while key experiments are used to prove what role DMT plays in the body such as a neurotransmitter and/or a hormone.

Published
June 13, 2022
Journal
Journal of Psychopharmacology
Authors
Jiménez, J. H., Bouso, J. C.
Open Accessindividual

Associations between lifetime classic psychedelic use and cardiometabolic diseases

Using NSDUH 2005–2014 data, respondents reporting lifetime classic psychedelic use had lower adjusted odds of past‑year heart disease (aOR 0.77, 95% CI 0.65–0.92) and diabetes (aOR 0.88, 95% CI 0.78–0.99). The authors suggest classic psychedelics might benefit cardiometabolic health but emphasise the need for research to establish causal mechanisms.

Published
July 13, 2021
Journal
Scientific Reports
Authors
Simonsson, O., Osika, W., Carhart-Harris, R. L., Hendricks, P. S.
Open Accessindividual

N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain

This rat study (n=69) examined whether DMT (1mg/kg/h) administration achieves neuroprotection via Sig-1R activation during an experimentally induced forebrain ischemia in rats and found that DMT attenuated the electrophysiological signature neurodegeneration even when 5-HTR binding was inhibited with a serotonergic antagonist, which confirmed the neuroprotective role of Sig-1R activation in their hypothesis.

Published
May 21, 2021
Journal
Neuropharmacology
Authors
Szabó, Í., Varga, V. É., Dvorácskó, S., Farkas, A. E., Körmöczi, T., Berkecz, R., Kecskés, S., Menyhárt, Á., Frank, R., Hantosi, D., Cozzi, N. V., Frecska, E., Tömböly, C., Krizbai, I. A., Bari, F., Farkas, E.
Paywallindividual

Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year

Using nationally representative US survey data (NSDUH 2005–2014), lifetime use of classic psychedelics was associated with lower odds of past‑year hypertension after adjustment (adjusted odds ratio 0.86, 95% CI 0.81–0.91), an effect driven specifically by lifetime tryptamine use (aOR 0.80, 95% CI 0.73–0.89). These cross‑sectional findings suggest a potential protective link but cannot establish causality; randomised controlled trials are needed to probe mechanisms and causal effects on blood pressure.

Published
May 1, 2021
Journal
Hypertension
Authors
Simonsson, O., Hendricks, P. S., Carhart-Harris, R., Kettner, H., Osika, W.

Clinical Trials

1 trial
RecruitingPhase NA

Antidepressant Response of DMT Masked With Propofol (DMT4D)

This randomised, placebo-controlled, quadruple-masked trial (n=112) will investigate whether the antidepressant effects of DMT (2 mg/min over 20 minutes; total ~40 mg) in patients with MDD depend on the subjective psychedelic experience by comparing DMT vs placebo under propofol sedation or no sedation.

Started
April 1, 2025
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06927076

Explore further

Search all DMT papers Search all Immunology & Inflammation trials Full DMT profile Full Immunology & Inflammation profile